| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -50.0 | -30.3 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ORKA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Oruka Therapeutics, Inc.: key numbers
- Share price
- $99.24Close, Nov 16
- Market cap
- $6.73B
- Shares outstanding
- 67.82MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oruka Therapeutics, Inc.
All →Oruka Therapeutics CMO Joana Goncalves Sells $707K of Stock
Joana Goncalves, CMO, sold 7,000 shares of Oruka Therapeutics, Inc. at $99.52 to $105.86 a share (average $100.96) in 6 transactions, worth $707K in total on Nov 16, 2026. Shares held after the trade: 31,771 (-1.5%).
- Value
- $707K
- Shares
- 7,000
- Average price
- $100.96
- Role
- CMO
- Holding change
- -1.5%
- Trade date
- Nov 16, 2026
Oruka Therapeutics SVP, Finance Arjun Agarwal Sells $1.05M of Stock
Arjun Agarwal, SVP, Finance, sold 10,000 shares of Oruka Therapeutics, Inc. at $101.98 to $107.00 a share (average $104.97) in 6 transactions, worth $1.05M in total on Nov 12, 2026. Shares held after the trade: 14,219 (-0.7%).
- Value
- $1.05M
- Shares
- 10,000
- Average price
- $104.97
- Role
- SVP, Finance
- Holding change
- -0.7%
- Trade date
- Nov 12, 2026
Oruka Therapeutics Insider Kristine M. Ball Sells $1.89M of Stock
Kristine M. Ball sold 18,000 shares of Oruka Therapeutics, Inc. at $102.10 to $106.98 a share (average $104.93) in 6 transactions, worth $1.89M in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $1.89M
- Shares
- 18,000
- Average price
- $104.93
- Holding change
- -100.0%
- Trade date
- Nov 12, 2026
Oruka Therapeutics CEO Lawrence Otto Klein Sells $2.39M of Stock
Lawrence Otto Klein, CEO, sold 25,000 shares of Oruka Therapeutics, Inc. at $94.77 to $98.40 a share (average $95.60) in 5 transactions, worth $2.39M in total on Nov 2, 2026. Shares held after the trade: 923,128 (-0.0%).
- Value
- $2.39M
- Shares
- 25,000
- Average price
- $95.60
- Role
- CEO
- Holding change
- -0.0%
- Trade date
- Nov 2, 2026
Oruka Therapeutics Clinical Trial Data
Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.
Oruka Therapeutics General Counsel Paul T. Quinlan Sells $707K of Stock
Paul T. Quinlan, General Counsel, sold 9,000 shares of Oruka Therapeutics, Inc. at $74.90 to $79.49 a share (average $78.53) in 5 transactions, worth $707K in total on Oct 20, 2026. Shares held after the trade: 29,995 (-9.1%).
- Value
- $707K
- Shares
- 9,000
- Average price
- $78.53
- Role
- General Counsel
- Holding change
- -9.1%
- Trade date
- Oct 20, 2026